The fact that AML LSC reside in multiple fractions of CD34+ cells, and sometimes (rarely) even in CD34‐negative cell populations in some AML variants,21 is an important issue when considering effective cell therapies and immunotherapies. This evidence concerns the gene CD34 and acute myeloid leukemia.